A comparative study between the dispersible Ferric pyrophosphate particles and Ferrous sulfate in treatment of pediatric patients with iron deficiency anemia

2021 ◽  
Author(s):  
Fady M. El-Gendy ◽  
Ayat A El- Gendy ◽  
Mahmoud A. El-Hawy
Keyword(s):  
Side Effects ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Ferrous Sulfate ◽  
Complete Blood Count ◽  
Deficiency Anemia ◽  
P Value ◽  
Liquid Form ◽  
Ferric Pyrophosphate ◽  
Significant Difference

Background: Iron deficiency anemia (IDA) is the most common type of anemia related to malnutrition worldwide. It represents a major problem in developing countries, especially in Egypt. Ferric pyrophosphate (FPP) is a water-insoluble iron compound often used to fortify infant cereals and chocolate drink powders. It causes no adverse color and flavor changes to food vehicles. This study was done to compare the efficacy of FPP (micro dispersed iron) and ferrous sulfate (FS) in treating childhood IDA. Materials and Methods: This prospective cohort study was conducted on 58 anemic children visiting the outpatient clinic, pediatric department of Menoufia University hospitals from March 2017 to June 2019. The inclusion criteria of the involved children were age 2 - 12 years and the diagnosis of IDA. Patients with other types of anemia were excluded from the study. Verbal permission was obtained from the parents of the children according to the ethical committee of Menoufia University. Patients were randomly divided into 2 groups. Group1 included 29 children who were treated with FPP and group2 included 29 children who were treated with oral traditional iron in the form of FS. Complete blood count and iron profile were recorded before and after 8 weeks of treatment. Results: The results showed no statistically significant difference between the FPP group and the FS group regarding clinical examinations (P-value > 0.05). There was no significant difference regarding hemoglobin, serum iron, and serum ferritin between the FPP and the FS groups after treatment (P-value> 0.05). However, side effects were significantly higher in the FS group (P-value > 0.001). Conclusion: Micro dispersed iron could be used as an alternative therapy for children with IDA who refuse oral iron therapy in a liquid form with more tolerability and fewer side effects.

scholarly journals Lactoferrin Efficacy versus Ferrous Sulfate in Treatment of Children with Iron Deficiency Anemia

2021 ◽  
Vol 11 (01) ◽  
pp. e199-e204
Author(s):  
Osama Mahmoud El-Asheer ◽  
Ahmed Gaber Ahmed ◽  
Zainab AbdelAal Abdel Hafez ◽  
Marwa AbdelHafiz Dahpy ◽  
Amal AbdElSalam Soliman
Keyword(s):  
Side Effects ◽  
Iron Deficiency ◽  
Patient Compliance ◽  
Iron Deficiency Anemia ◽  
Ferrous Sulfate ◽  
Serum Iron ◽  
Deficiency Anemia ◽  
Serum Transferrin ◽  
Iron Binding ◽  
Clinical Benefits

AbstractLactoferrin (LF) is an iron-binding globular glycoprotein that is structurally and chemically similar to serum transferrin. Many studies have been done to evaluate the effect of oral LF administration on iron deficiency anemia (IDA) with controversial results. This study was designed to compare the efficacy of LF versus oral ferrous sulfate (OFS) therapy in the treatment of children with IDA. A significant increase in mean hemoglobin and serum iron concentrations was noted in the group that received oral bovine LF (11.06 ± 0.96 and 42.79 ± 6.14, respectively) versus the group that received OFS (10.24 ± 0.57 and 28.94 ± 5.05, respectively, with p < 0.001 for each) after 30 days of the treatment with fewer side effects (9.3 vs. 33.3% with p = 0.043). Oral bovine LF is a more effective and safer alternative in treating iron deficiency and IDA compared with OFS with clinical benefits of fewer side effects and better patient compliance.

scholarly journals Ferrous sulfate in the treatment of iron deficiency anemia: The positions continue

2017 ◽  
Vol 89 (10) ◽  
pp. 108-112
Author(s):  
L I Dvoretsky
Keyword(s):  
Side Effects ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Ferrous Sulfate ◽  
Dosage Form ◽  
Iron Sulfate ◽  
Deficiency Anemia ◽  
Iron Release ◽  
Comparative Efficacy ◽  
Peroxidation Processes

The paper discusses treatment strategy and tactics for iron deficiency anemia. It gives data on the comparative efficacy of different iron sulfate drugs, their bioavailability, effects on peroxidation processes, and side effects. The paper also considers the clinical significance of a dosage form of iron-containing drugs with a sustained iron release, as well as ways to reduce the frequency and magnitude of side effects when ferrous sulfate is used.

scholarly journals Catfish Oil (Pangasius hypophthalmus) effect to ferritin and sTfR in iron deficiency anemia

2021 ◽  
Vol 10 (1) ◽  
pp. 28-35
Author(s):  
Hersanti Sulistyaningrum ◽  
Fronthea Swastawati ◽  
Maria Mexitalia ◽  
Etika Ratna Noer
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Ferrous Sulfate ◽  
Wistar Rats ◽  
Heme Iron ◽  
Deficiency Anemia ◽  
Significant Difference ◽  
Before And After ◽  
Male Wistar Rats ◽  
Catfish Oil

Background: Iron deficiency anemia is a micronutrient problem and the prevalence is still high. Catfish oil (Pangasius hypophthalmus) is a natural source of heme iron which can improve body iron levels.Objectives: This study was aimed to examine and analyze the effect of catfish oil on ferritin and sTfR levels in male wistar rats with iron deficiency anemia models.Materials and Methods: This study was conducted on male wistar rats which were divided into groups C- (standard feed), C+ (standard feed but had the iron removed), X1 (standard feed without iron but was supplemented with catfish oil), X2 (standard feed without iron but was supplemented with ferrous sulfate) for 14 days. Ferritin and sTfR levels were measured before and after intervention using ELISA.Results: The study showed an increase ferritin levels in X1 (21.87 ng/ml ±0.76), X2 (24.47 ng/ml ±0.54) and there was no significant difference between the two (p=0.069; p>0.05); a decrease in C- (0.25 ng/ml ±0.43), C+ (0.32 ng/ml ±0.059) (p=0.00; p<0.05). The sTfR levels decreased before and after intervention (p=0.00; p<0.05) in C+ (0.24 μ/mL ±0.99), X1 (60.66 μ/mL ±0.29), X2 (62.10 μ/mL ±0.90) and increased in C- (0.40 μ/mL ±0.97).Conclusions: The study indicates ferritin levels increased in the rats receiving catfish oil is not different from the rats that received ferrous sulfate and sTfR levels decreased significantly in wistar rats with iron deficiency anemia receiving catfish oil although the results were not as good as ferrous sulfate supplementation

scholarly journals THE PREVALENCE OF CELIAC DISEASE IN PATIENTS WITH IRON-DEFICIENCY ANEMIA IN CENTER AND SOUTH AREA OF IRAN

2015 ◽  
Vol 52 (4) ◽  
pp. 278-282 ◽  
Author(s):  
Mahmud BAGHBANIAN ◽  
Ali FARAHAT ◽  
Hasan Ali VAHEDIAN ◽  
Elham SHEYDA ◽  
Mohamad Reza ZARE-KHORMIZI
Keyword(s):  
Celiac Disease ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Significant Relationship ◽  
Tissue Transglutaminase ◽  
Deficiency Anemia ◽  
P Value ◽  
Pathological Changes ◽  
Positive Serology ◽  
Significant Difference

Background - Celiac disease is an immune-mediated enteropathy due to a permanent sensitivity to gluten in genetically susceptible people. Iron-deficiency anemia is the most widely experienced anemia in humans. Iron-deficiency anemia additionally is a common extra intestinal manifestation of celiac disease. Objective - To investigate correlation between tTg levels and histological alterations and then to determine the prevalence of celiac disease in Center and South area patients of Iran with iron deficiency anemia. Methods - A total of 402 patients aged 12-78 years who presented with iron-deficiency anemia were included in this study. Hemoglobin, mean corpuscular volume and serum ferritin were determined. Venous blood samples for anti-tissue transglutaminase antibody immunoglobuline A and G were obtained from these patients. Upper gastrointestinal endoscopy was recommended to patients who had positive serology. Results - Of 402 patients with iron-deficiency anemia, 42 (10.4%) had positive serology for celiac disease. The small intestine biopsy of all patients with positive serology showed pathological changes (Marsh I, II & III). There was not significant difference in the mean hemoglobin level between iron-deficiency anemia patients with celiac disease and without celiac disease, duodenal biopsy results did not show significant relationship between the severity of pathological changes and levels of anti-tTG IgG (P -value: 0/869) but significant relationship was discovered between pathological changes and levels of anti-tTG IgA (P -value: 0/004). Conclusion - Screening of celiac disease by anti-tissue transglutaminase antibody should be completed as a routine investigation in patients with iron-deficiency anemia. Also physicians must consider celiac disease as a possible reason of anemia in all patients with iron deficiency anemia.

SOLUBLE TRANSFERRIN RECEPTOR IS A PROMISING MARKER of IRON DEFICIENCY ANEMIA IN PREVALENT HEMODIALYSIS PATIENTS

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Khaled Abou seif ◽  
Hussien Sayed Hussien ◽  
Shaimaa Abdelmegied ◽  
Marwa Abdulhady
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Transferrin Receptor ◽  
Iron Status ◽  
Hemodialysis Patients ◽  
Deficiency Anemia ◽  
P Value ◽  
Soluble Transferrin Receptor ◽  
Significant Difference ◽  
And Control

Abstract: Background Diagnosis of iron deficiency is traditionally based on ferritin and other iron parameters becomes difficult in end stage renal disease patients due to the inflammatory condition which affects these markers and masks the iron deficiency. Serum soluble transferrin receptor (sTfR) is able to be a reliable indicator for assessing iron status, as it is not affected by inflammatory procedures. Aim To evaluate the usefulness of serum soluble transferrin receptors in iron deficiency anemia detection in comparison to the classic markers of iron status in prevalent hemodialysis patients. Methods This case-control study assessed sTfR in 80 prevalent ESRD patients on regular hemodialysis in 2 groups. Group A (N = 40): CRP &gt;10 and group B (N = 40):CRP &lt;10 and apparently healthy 8 control subjects. Results The cut of value of STFRs in hemodialysis patients was 12.5 mg\l. The prevalence of STFRs in patients with CRP&lt;10 was 85%, while in patients with CRP&gt;10 was 92.5% (P-value 0.288). STFRs have high sensitivity 88.75, specificity 100, PPV100% and NPV 47.1%. The hemodialysis patients who have elevated STFRs have risk 1.22 times to have iron deficiency anemia if CRP &lt;10 (odds ratio: 1.22) and 3.14 times if CRP&gt;10 (odds ratio: 3.14). There was significant difference on comparing patients with CRP&lt;10, CRP&gt;10 and control as regard Hb and STFR with P-value 0.0001 and 0.0001 respectively. Post Hoc analysis showed significant difference in both between the patients with CRP&lt;10 and control also in patients with CRP&gt;10 and control (p value &lt;0.0001). while on comparing patients with CRP&lt;10 with patients with CRP&gt;10 there was significant difference in STFRs p value 0.0001 despite no significant difference in hemoglobin (p value 0.642) and classic marker of iron deficiency (s.iron, TIBC, TSAT) with p value 0.701,0.192,0.382 respectively. Serum STFRs was negatively correlated with s.iron and Kt\v (r -0.372, P-value 0.018) and (r-0.416, p value 0.008) respectively in patients with CRP &lt;10. Conclusion Serum soluble transferrin receptor is highly sensitive and specific marker for iron deficiency in hemodialysis patients especially in patients with high CRP level.

Prevalence of Iron Deficiency Anemia in Hemodialysis patients at NIKD

2021 ◽  
Vol 15 (6) ◽  
pp. 1192-1194
Author(s):  
A. Amjad ◽  
S. Usmani ◽  
H. H. Pasha ◽  
W. A. Khan ◽  
M. A. Qamar ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Complete Blood Count ◽  
Binding Capacity ◽  
Hemodialysis Patients ◽  
Deficiency Anemia ◽  
P Value ◽  
Serum Samples ◽  
Cross Sectional ◽  
Iron Binding Capacity

Background: Iron deficiency is a cause of anemia in many hemodialysis patients. It remains under diagnosed in patients with kidney diseas and it leads to inappropriate response to erythropoietin. Early diagnosis of this anemia before usage of erythropoietin is important, to prevent prescription of expensive erythropoietin and unnecessary costs to the patient and the health care system. This study was conducted to determine prevalence of iron deficiency anemia in hemodialysis patients. Methods: This study was cross-sectional comparative study and was conducted at National Institute of Kidney Disease. Sheikh Zayed hospital nephrology department after taking permission from concerned department. Informed consent was taken from patients also. We measured serum ferritin, serum iron, Total iron binding capacity, complete blood count, hemoglobin in 140 hemodialysis patients. Serum samples were taken, processed and assessed for ferritin levels using commercially available ELISA kits. P value less than ≤ 0.05 was considered statistically significant. Results: Out of 140 hemodialysis patients, 34 had Iron deficiency anemia . (IDA). Conclusion: Iron deficiency anemia was observed in 24.2 % of hemodialysis patients

scholarly journals Assessing the Efficacy of Bovine Lactoferrin to Correct Iron Deficiency Anemia in Non-pregnant Non-lactating Women: A Randomized Controlled Trial (FS08-02-19)

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Tanvir Huda ◽  
Michael Dibley ◽  
Shams El Arifeen ◽  
Sajia Islam ◽  
Nazia Ali ◽  
...  
Keyword(s):  
Side Effects ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Ferrous Sulfate ◽  
Reproductive Age ◽  
Deficiency Anemia ◽  
Bovine Lactoferrin ◽  
Women Of Reproductive Age ◽  
Lactating Women ◽  
Line P

Abstract Objectives 1. To determine if bovine lactoferrin (bLf) is at least as effective as oral ferrous sulfate in iron deficiency anemia in non-pregnant women of reproductive age (WRA) 2. To determine the optimal dose of oral bLf 3. To compare the side-effects of the treatments Methods Design: Non-inferiority, double-blind, individually RCT in non-pregnant WRA with iron deficiency anemia (Hb <12 g/dl & serum ferritin <30 μg/L) Setting: Mirpur, Dhaka, Bangladesh Participants: 555 non-pregnant, non-lactating women of 15–49 years. Interventions: Women were allocated individually (1:1:1) in three arms. Arm A, B and C received daily oral 200 mg bLf, 400 mg bLf and 60 mg ferrous sulfate. All received 400 μg of folic acid daily. Treatment was for 12 weeks. Outcomes: Serum Hb and serum ferritin at baseline and every 30 days for 3 months. Inflammatory markers: C-reactive protein (CRP); alpha(1)-Acid glycoprotein (AGP); hepcidin, at baseline and end line. Possible adverse effects were assessed. Results Women on 200 mg bLf had a decrease in Hb of 0.3 g/dl (95% CI, −0.60 to 0.00 g/dl, P = 0.05), women on 400 mg bLf arm had no change in Hb: 0.0 g/dl (95% CI, −0.32 to 0.32 g/dl, P = 1.00), and women on ferrous sulfate arm had an increase in Hb: 1.1 g/dl (95% CI, 0.83 to 1.37 g/dl, P < 0.0001). Women on 200 mg bLf had an increase in ferritin: 2.8 μg/l (95% CI, 0.38 to 5.22 μg/l, P = 0.02), women on 400 mg bLf had an increase in ferritin: 3.5 μg/l (95% CI, 0.64 to 6.36 μg/l, P = 0.02) and women on ferrous sulfate arm had an increase in ferritin: 41.1 μg/l (95% CI, 35.74 to 46.47 μg/l, P < 0.0001). There were no significant differences in AGP and CRP between arms at the base line (P = 0.38 and 0.95) and end line (P = 0.87 and 0.14). Those on ferrous sulfate had a significant increase in hepcidin concentration after 90 days (P = .000). Abdominal pain, indigestion, diarrhea and black stool were significantly higher on ferrous sulfate group. There were no differences for other side-effects across treatment arms Conclusions Ferrous sulfate has better efficacy than bLf for iron deficiency anemia in non-pregnant non-lactating women of reproductive age in urban Bangladesh. This lactoferrin product may be inactive, or there may have been inadequate dietary iron for bLF to promote its absorption. Funding Sources Saving Lives at Birth and Medical Research Council, UK.

scholarly journals Is There Any Correlation between Migraine Attacks and Iron Deficiency Anemia? ACase-Control Study

2019 ◽  
Author(s):  
Ali Tayyebi ◽  
Maryam Poursadeghfard ◽  
Masoumeh Nazeri ◽  
Tahereh Pousadeghfard
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Serum Ferritin ◽  
Case Control ◽  
Deficiency Anemia ◽  
P Value ◽  
Iron Storage ◽  
Body Iron ◽  
Significant Difference ◽  
Sound Sensitivity

Background: Migraine headache is an episodic abnormality which usually presents with a severe headache, accompanied by nausea, photo and sound sensitivity, and autonomic symptoms. Iron accumulation in brain, especially peri-aqueductal grey is associated with duration of the disease, and apparently there is an association between body iron storage status and the incidence of migraine; hence, the present study was conducted to investigate the plausible association between iron-deficiency anemia and migraine in a case-control design. Materials and Methods: After signing the written informed consent, the blood samples were collected by a well-trained technician from the patients proved to have migraine, those having migraine clinical criteria and those having migraine attack frequency as high as that prophylaxis was required, and non-migraine healthy individuals, those having not migraine and anemia except iron-deficiency anemia. Based on the sample size, each group composed of samples with at least 100 individuals. Results: There were statistically significant differences between female cases and controls regarding hemoglobin, serum ferritin levels and iron-deficiency anemia (P-value: .0004; .006; .001), but no differences were observed among males (P-value: .606; .38; .303). Furthermore, the case-control comparisons revealed a significant difference in iron-deficiency anemia (P-value: .032), but no significant difference was seen in hemoglobin and serum ferritin levels (P-value: .161; .178). Conclusion: The present study suggests an association between iron-deficiency anemia, hemoglobin and serum ferritin levels and the incidence of migraine in females. As a result, there might be an association between body iron storage status and the incidence of migraine, especially among females, reflecting the fact that iron supplements might be an effective treatment or prophylaxis in patients with migraine associated with iron-deficiency anemia. However, further studies are required to provide a conclusive answer to the issues remained controversial.

scholarly journals IRON DEFICIENCY ANEMIA

2009 ◽  
Vol 16 (02) ◽  
pp. 209-215
Author(s):  
SHAHEEN AHMED ◽  
Salman Ali ◽  
NAEEM FAREED ◽  
Mehboob Sultan ◽  
NADEEM SADIQ ◽  
...  
Keyword(s):  
Single Dose ◽  
Side Effects ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Serum Ferritin ◽  
Successful Treatment ◽  
Ferrous Sulfate ◽  
Deficiency Anemia ◽  
Control Group ◽  
Single Versus

t r o d u c t i o n : The adherence to treatment of iron deficiency anemia often is poor in both developed and developingcountries. The current standard therapy is oral ferrous sulfate administered 3 times daily. It is possible that adherence would improve witha single-dose daily treatment regimen. O b j e c t i v e s : To compare single versus thrice daily ferrous sulfate for treatment of iron deficiencyanemia in young children. D e s i g n : Quasi experimental study Setting: Children Department Military Hospital Rawalpindi. P e r i o d : From (01Jan- to31 Mar 05 and 03 Jul to 02 Oct 05) Subjects and Methods: Total 250 patients of iron deficiency anemia (hemoglobin values: 7.0to 9.9 gm/dl and serum ferritin values: 10 ng/ml or less) were identified. Children divided into two groups and matched on the basis of age;and gender. One group (n = 125) received ferrous sulfate once daily and the control group (n = 125) received ferrous sulfate thrice dailyat a total dose of 6 mg/kg/day of elemental iron for 2 months. Hemoglobin and serum ferritin values were measured as baseline and at theend of the study. R e s u l t s : Successful treatment of anemia (target hemoglobin > 10 gm/dl) occurred in 81.42 % of the single dose and in79.83 % of thrice daily dose groups and the side effects were minimal between the two groups. Conclusion: A single versus a 3 times dailydose of ferrous sulfate resulted in a similar rate of successful treatment of iron deficiency anemia, without significant side effects.

scholarly journals Ferrous sulfate liquid for the treatment of iron deficiency anemia

1981 ◽  
Vol 21 (1-2) ◽  
pp. 21
Author(s):  
Soemantri Soemantri ◽  
A. G. Soedigbia ◽  
I. Hardiman ◽  
Taty Hendarto ◽  
Widjaja Widjaja
Keyword(s):  
Side Effects ◽  
Iron Deficiency ◽  
Vitamin C ◽  
Iron Deficiency Anemia ◽  
Ferrous Sulfate ◽  
Deficiency Anemia ◽  
Control Group ◽  
High Dose

A study on the effect of ferrous sulfate liquid (lberet - 500 liquid) was conducted on a group of well-nourished children aged 6 months - 5 years.After 3 months 0/ treatment, hematological measurements revealed a statistically significant improvement as compared to the control group receiving placebo. Side effects were also found to be minimal. Thus ferrous sulfate liquid is recommended for treatment or supplement to anemia eradication, preferably associated with a high dose of vitamin C.

Sign in / Sign up

Export Citation Format

Share Document